WOM (World of Medicine) fails to reach sales goal in 2002
This article was originally published in Clinica
World of Medicine (WOM), a company that manufactures products for minimally invasive surgery, including lasers and insufflation pump systems, experienced a difficult financial year in 2002, with sales rising barely 2% to E30.9m ($32.8m). The Ludwigsstadt, Germany-based company made a loss before interest and tax of E1.9m, compared with a profit of E0.6m for the previous year, putting the company in the red for the first time in six years. "We are not satisfied with this result, as our goals for 2002 were set much higher," said WOM's CEO, Peter Wiest.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.